Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. PDS Biotechnology Corporation shares valued at $25,000 were purchased by Freitag Gregory Gene on Feb 28 ’25. At $1.66 per share, Freitag Gregory Gene acquired 15,060 shares. The insider’s holdings grew to 61,213 shares worth approximately $77740.51 following the completion of this transaction.
Also, Glover Stephen C. purchased 15,061 shares, netting a total of over 25,001 in proceeds. Following the buying of shares at $1.66 each, the insider now holds 78,851 shares.
As published in their initiating research note from B. Riley Securities on November 01, 2022, PDS Biotechnology Corporation [PDSB] has been a Buy and the price target has been revised to $10. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late June. As of November 10, 2020, H.C. Wainwright has increased its “Neutral” rating to a “Buy” for PDSB. Earlier on May 27, 2020, Alliance Global Partners initiated its rating. Their recommendation was “a Buy” for PDSB stock.
Analyzing PDSB Stock Performance
On last trading session,, PDS Biotechnology Corporation [NASDAQ: PDSB] rose 4.10% to $1.27. The stock’s lowest price that day was $1.18, but it reached a high of $1.32 in the same session. During the last five days, there has been a drop of approximately -15.89%. Over the course of the year, PDS Biotechnology Corporation shares have dropped approximately -56.66%. Shares of the company reached a 52-week high of $2.2000 on 02/27/25 and a 52-week low of $0.8500 on 04/07/25.
Support And Resistance Levels for PDS Biotechnology Corporation (PDSB)
According to the 24-hour chart, there is a support level at 1.1933, which, if violated, would cause prices to drop to 1.1167. In the upper region, resistance lies at 1.3333. The next price resistance is at 1.3967. RSI (Relative Strength Index) is 37.10 on the 14-day chart, showing neutral technical sentiment.
Is PDS Biotechnology Corporation subject to short interest?
Stocks of PDS Biotechnology Corporation saw a sharp steep in short interest on 2025-06-13 dropping by -0.89 million shares to 1.99 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 2.88 million shares. A decline of -44.66% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.34 of the overall float, the days-to-cover ratio (short ratio) decline to 2.34.
Which companies own the most shares of PDS Biotechnology Corporation (PDSB)?
In terms of PDS Biotechnology Corporation share price expectations, FactSet research, analysts set an average price target of 9 in the next 12 months, up nearly 637.7% from the previous closing price of $1.22. Analysts anticipate PDS Biotechnology Corporation stock to reach 9 by 2025, with the lowest price target being 9. In spite of this, 2 analysts ranked PDS Biotechnology Corporation stock as Buy at the end of 2025. On March 09, 2020, Noble Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $5.45.
